Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
Antiviral Therapy2010Vol. 15(8), pp. 1107–1114
Citations Over TimeTop 11% of 2010 papers
Li Zhu, Joan R. Butterton, Anna Persson, M. Stonier, Wendy Comisar, Deborah Panebianco, Sheila Breidinger, Jenny Zhang, Richard Bertz
Abstract
Coadministration of atazanavir and raltegravir 300/400 mg twice daily decreased atazanavir AUC(0-12) and C(min) relative to atazanavir alone, and increased AUC(0-12) of raltegravir relative to raltegravir alone. Atazanavir and raltegravir alone and coadministered appeared safe and well-tolerated.
Related Papers
- → Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection(2013)99 cited
- Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.(2015)
- → Severe insomnia related to high concentrations of raltegravir(2011)17 cited
- → Cobicistat: a guide to its use as a pharmacokinetic enhancer of atazanavir and darunavir in HIV-1 infection(2014)2 cited
- → Cobicistat vs. Ritonavir as a Booster for Atazanavir(2011)